Procter & Gamble Health growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+7.4%−33.4%
EBITDA+10.3%−32.5%
Net Income+45.3%−25.2%
EPS (adj.)+45.3%−25.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PGHL₹5,399.00

Procter & Gamble Health Limited

· Pharma & Health
₹ CrorePeersSANOFICONRSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCASTRAZENMcap ₹8,962 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+7.4-33.4
EBITDA+10.3-32.5
Net Income+45.3-25.2
EPS (adj.)+45.3-25.2
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY27 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.